Age-Related Macular Degeneration (AMD) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Artificial Intelligence-Based Predictions in Neovascular AMD Artificial Intelligence-Based Predictions in Neovascular AMD
What role could artificial intelligence have in the clinical management of neovascular age-related macular degeneration?Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 3, 2021 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Bayer Middle East brings Alleye home monitoring programme to Egypt
The German pharma giant is working with top eye hospitals in the country to support virtual care for patients with Diabetic Macular Edema or age-related macular degeneration. (Source: mobihealthnews)
Source: mobihealthnews - September 3, 2021 Category: Information Technology Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) ...
Source: Roche Media News - July 29, 2021 Category: Pharmaceuticals Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) ...
Source: Roche Investor Update - July 29, 2021 Category: Pharmaceuticals Source Type: news

FDA Accepts Application for Genentech ’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
South San Francisco, CA -- July 28, 2021 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA),... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 28, 2021 Category: Drugs & Pharmacology Source Type: news

FDA accepts application for Roche ’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 24 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). Neovascular AMD is a leading cause of blindness for people aged 60 and over and impacts approximatel y 20 million people worldwide.1,2,3 If approved, PDS would be a first-of-its-kind therapeutic approach, offering people living with nAMD an alternative to frequent eye injections of...
Source: Roche Investor Update - June 24, 2021 Category: Pharmaceuticals Source Type: news

FDA accepts application for Roche ’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 24 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). Neovascular AMD is a leading cause of blindness for people aged 60 and over and impacts approximatel y 20 million people worldwide.1,2,3 If approved, PDS would be a first-of-its-kind therapeutic approach, offering people living with nAMD an alternative to frequent eye injections of...
Source: Roche Media News - June 24, 2021 Category: Pharmaceuticals Source Type: news

Recycling of the eye's light sensors is faulty in progressive blindness of older adults
(University of Maryland School of Medicine) With the National Eye Institute reporting that about 11 million older adults in the U.S. endure a condition that leads to progressive blindness, known as age-related macular degeneration, University of Maryland School of Medicine (UMSOM) researchers are starting to understand what goes wrong in the disease, in order to develop new therapies to treat it. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 23, 2021 Category: International Medicine & Public Health Source Type: news

Scientists unravel the function of a sight-saving growth factor
(NIH/National Eye Institute) Researchers at the National Eye Institute (NEI) have determined how certain short protein fragments, called peptides, can protect neuronal cells found in the light-sensing retina layer at the back of the eye. The peptides might someday be used to treat degenerative retinal diseases, such as age-related macular degeneration (AMD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 16, 2021 Category: International Medicine & Public Health Source Type: news

A frozen leap forward
(University of California - Santa Barbara) Scientists at UC Santa Barbara, University of Southern California (USC) and biotechnology company Regenerative Patch Technologies LLC (RPT) have reported new methodology for preservation of RPT's stem cell-based therapy for age-related macular degeneration (AMD). (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 14, 2021 Category: Biology Source Type: news

Does age-related macular degeneration (AMD) treatment influence patient falls and mobility? A systematic review - Garrigan H, Hamati J, Lalakia P, Frasso R, Salzman B, Hyman L.
PURPOSE: Age-related macular degeneration (AMD), a leading cause of irreversible blindness, increases fall risk through impaired central vision. Falls place an enormous economic burden on healthcare systems. We hypothesized that AMD treatments may reduce p... (Source: SafetyLit)
Source: SafetyLit - May 20, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Photobiomodulation Therapy in ARMD Photobiomodulation Therapy in ARMD
Is photobiomodulation therapy an effective treatment option for exudative and nonexudative AMD?Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 5, 2021 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
SEATTLE, April 7, 2021 -- (Healthcare Sales & Marketing Network) -- LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced positive findings in its LIGHTSIT... Devices, Ophthalmology LumiThera , photobiomodulation, Age-Related Macular Degeneration (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 7, 2021 Category: Pharmaceuticals Source Type: news

Lab model offers hope for macular degeneration patients
(University of Rochester) University of Rochester researchers have created a 3D lab model using patient-derived tissues that mimics the areas of the retina affected in age-related macular degeneration (AMD), which affects an estimated 196 million people. They believe this could lead to finding specific drugs for individual patients to treat a disease that currently has no cure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2021 Category: International Medicine & Public Health Source Type: news

Gene therapy trial for age-related macular degeneration now open at Columbia
(Columbia University Irving Medical Center) A clinical trial to test a gene therapy for some patients with dry age-related macular degeneration -- a leading cause of blindness in the United States -- is underway at Columbia and NewYork-Presbyterian. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2021 Category: International Medicine & Public Health Source Type: news